Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy.

Oleksandr Valentynovych Oliynyk Wojciech BargAnna SlifirczykYanina OliynykSerhij DubrovVitaliy GurianovMarta Rorat

Published in: Life (Basel, Switzerland) (2021)

The use of unfractionated heparin in the treatment of COVID-19-associated coagulopathy seems to be more effective at reducing the risk of intubation and death than enoxaparin at prophylactic doses.

Keyphrases

venous thromboembolism
coronavirus disease
sars cov
growth factor
respiratory syndrome coronavirus
combination therapy